Lucinda Melcher
A5102743053- Genetic factors in colorectal cancer
- Colorectal Cancer Screening and Detection
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Prostate Cancer Treatment and Research
- Colorectal and Anal Carcinomas
- Colorectal Cancer Surgical Treatments
- Prostate Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Esophageal Cancer Research and Treatment
- COVID-19 and healthcare impacts
- Lung Cancer Diagnosis and Treatment
- Healthcare cost, quality, practices
- Sexual Differentiation and Disorders
- Radiopharmaceutical Chemistry and Applications
- Hormonal and reproductive studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Lipids, and Metabolism
- COVID-19 Clinical Research Studies
- Body Contouring and Surgery
- Bladder and Urothelial Cancer Treatments
- Lung Cancer Treatments and Mutations
- Medical Imaging Techniques and Applications
- Multiple Myeloma Research and Treatments
- Cancer survivorship and care
North Middlesex University Hospital NHS Trust
2020-2024
North Middlesex Hospital
2014-2019
Beatson West of Scotland Cancer Centre
2015
Harefield Hospital
2004
Mount Vernon Hospital
2004
Large cohorts of patients with active cancers and COVID-19 infection are needed to provide evidence the association recent cancer treatment type mortality.
Abstract Purpose: The absence of postoperative circulating tumor DNA (ctDNA) identifies patients with resected colorectal cancer (CRC) low recurrence risk for adjuvant chemotherapy (ACT) de-escalation. Our study presents the largest CRC cohort to date tissue-free minimal residual disease (MRD) detection. Experimental Design: TRACC (tracking mutations in cell-free predict relapse early cancer) included stage I III resectable CRC. Prospective longitudinal plasma collection ctDNA occurred pre-...
In locally advanced rectal cancer (LARC) preoperative chemoradiation (CRT) is the standard of care, but risk local recurrence low with good quality total mesorectal excision (TME), although many still develop metastatic disease. Current challenges in treating include development effective organ-preserving approaches and prevention subsequent Neoadjuvant systemic chemotherapy (NACT) alone may reduce recurrences, be more than postoperative treatments which often have poor compliance....
BackgroundChemoradiation (CRT) or short-course radiotherapy (SCRT) are standard treatments for locally advanced rectal cancer (LARC). We evaluated the efficacy/safety of two neoadjuvant chemotherapy (NACT) regimens as an alternative prior to total mesorectal excision (TME).Methods/designThis multi-centre, phase II trial in patients with magnetic resonance imaging (MRI) defined high-risk LARC (>cT3b, cN2+ extramural venous invasion) randomised (1:1) FOLFOX + Bevacizumab (Arm 1) FOLFOXIRI...
4056 Background: Neoadjuvant chemotherapy using two cycles of cisplatin and 5FU is standard practice in the UK patients with potentially operable cancer esophagus. The role FDG-PET scanning predicting response to this was assessed. Method: Twenty-three disease at presentation underwent as OEO2 trial protocol. performed before chemotherapy, again after second cycle seventeen patients. Two independent assessors, who were unaware histopathological results, assessed percentage change tumour SUV...
<p>Venn diagrams of ctDNA detection by call method according to analysis population</p>
<p>Sensitivity analysis for landmark and longitudinal populations (n=33)</p>
<div>AbstractPurpose:<p>The absence of postoperative circulating tumor DNA (ctDNA) identifies patients with resected colorectal cancer (CRC) low recurrence risk for adjuvant chemotherapy (ACT) de-escalation. Our study presents the largest CRC cohort to date tissue-free minimal residual disease (MRD) detection.</p>Experimental Design:<p>TRACC (tracking mutations in cell-free predict relapse early cancer) included stage I III resectable CRC. Prospective longitudinal...
<p>TRACC B INVESTIGATORS</p>
<p>ctDNA detection rate at baseline and postoperative timepoints according to stage in the primary analysis population (n=143)</p>
<p>TRACC B INVESTIGATORS</p>
<p>Venn diagrams of ctDNA detection by call method according to analysis population</p>
<p>Bioinformatics review of patients with ctDNA detected no recurrence or death from CRC</p>
<p>Genotypic and epigenetic considerations</p>
<p>ctDNA detection rate at baseline and postoperative timepoints according to stage in the primary analysis population (n=143)</p>
<p>Bioinformatics review of patients with ctDNA detected no recurrence or death from CRC</p>
<div>AbstractPurpose:<p>The absence of postoperative circulating tumor DNA (ctDNA) identifies patients with resected colorectal cancer (CRC) low recurrence risk for adjuvant chemotherapy (ACT) de-escalation. Our study presents the largest CRC cohort to date tissue-free minimal residual disease (MRD) detection.</p>Experimental Design:<p>TRACC (tracking mutations in cell-free predict relapse early cancer) included stage I III resectable CRC. Prospective longitudinal...